MEG3 and metabolic dysfunction-associated steatotic liver disease: One of the first investigations of lncRNAs in NAFLD fibrosis demonstrated that MEG3 expression was decreased in livers from CCl4-treated mice compared to oil-fed control mice, and Meg3 expression diminished concordantly with the progression of fibrosis [21].